FIGURE 1



LAS 261 / CA-H2N-00-08
Mean Tumor Growth (mm³)
Days
Tumor Ctrl
ECD-PD(25)//SBAS2(1/10 human)
ECD-PD(25)//SBAS1B(1/10 human)
ECD-PD(25)//SBAS7A(1/10 human)
ECD-PD(25)//SBAS2 + SBAS7A(1/10 human)
ECD-PD(25)//SBAS6(1/10 human)
ECD-PD(25)//SBAS1B + SBAS7A(1/10 human)
0
50
100
150
200
250
300
350
0
10
20
30
40
50
60
70
80
90

FIGURE 2



ECD-PD in AS02B in Rhesus monkeys
mid.point
400000
300000
200000
100000
0
pre
14postIII
AS02B
AS01B
AS5
AS6
AS07A
AS02B+AS07A

FIGURE 4



In vivo tumor growth
Mean Tumor Growth (mm²)
Days
GP1
GP5
GP6
GP7
GP11
0
20
40
60
80
100
120
140
0
5
10
15
20
25
30
35
40

FIGURE 5



In vivo tumor growth
GP1
GP5
GP6
GP8
GP9
GP10
Mean Tumor Growth (mm²)
Days
0
20
40
60
80
100
120
140
0
5
10
15
20
25
30
35
40

FIGURE 6 - Lymphoproliferation (post vaccination, pre-tumour challenge)




FIGURE 7 - Lymphoproliferation (post tumour challenge)




FIGURE 8 - Total anti-ECD Ig response post vaccination.




FIGURE 9 - Isotype distribution induced by vaccines




FIGURE 10 - Lymphoproliferation post second P703 vaccination




FIGURE 11 - Lymphoproliferation post fourth P703 vaccination




FIGURE 12



serology
IgtoT @P703p(pichia)
Mid Point
12000
10000
8000
6000
4000
2000
0
1
3
6
2
4
5
groups

FIGURE 12



serology
IgtotP703p(pichia)
12000
10000
8000
6000
4000
2000
0
Mid Point
1
3
6
2
4
5
groups

FIGURE 13 - Anti- NS1-P703 Antibody titres induced by vaccination




FIGURE 14 - Anti-NS1-P703P Isotype distribution induced by vaccines

